Literature DB >> 11874829

Tumour necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors.

P J Mease1.   

Abstract

High levels of proinflammatory cytokines, including tumour necrosis factor (TNF), have been detected in psoriatic skin lesions and joints of patients with the inflammatory disease. Early results of treatment of psoriatic arthritis and psoriasis with TNF neutralising agents are encouraging, but whether these agents will be able to improve long term outcomes, such as disability, is not yet known.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11874829      PMCID： PMC1754073          DOI： 10.1136/ard.61.4.298

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


  60 in total

Review 1.  Recent developments in the understanding of the pathogenesis of psoriasis.

Authors:  J P Ortonne
Journal:  Br J Dermatol       Date:  1999-04       Impact factor: 9.302

2.  Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study.

Authors:  F Van den Bosch; E Kruithof; D Baeten; F De Keyser; H Mielants; E M Veys
Journal:  Ann Rheum Dis       Date:  2000-06       Impact factor: 19.103

Review 3.  Triggered psoriasis.

Authors:  R Wolf; V Ruocco
Journal:  Adv Exp Med Biol       Date:  1999       Impact factor: 2.622

Review 4.  Psoriatic arthritis.

Authors:  J M Moll; V Wright
Journal:  Semin Arthritis Rheum       Date:  1973       Impact factor: 5.532

5.  Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial.

Authors:  P J Mease; B S Goffe; J Metz; A VanderStoep; B Finck; D J Burge
Journal:  Lancet       Date:  2000-07-29       Impact factor: 79.321

6.  Proposed classification criteria of psoriatic arthritis. A preliminary study in 260 patients.

Authors:  B Fournié; L Crognier; C Arnaud; L Zabraniecki; V Lascaux-Lefebvre; V Marc; E Ginesty; V Andrieu; C Dromer; A Fournié
Journal:  Rev Rhum Engl Ed       Date:  1999-10

7.  Macrophage-derived cytokine and nuclear factor kappaB p65 expression in synovial membrane and skin of patients with psoriatic arthritis.

Authors:  C L Danning; G G Illei; C Hitchon; M R Greer; D T Boumpas; I B McInnes
Journal:  Arthritis Rheum       Date:  2000-06

8.  The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982-1991.

Authors:  M Shbeeb; K M Uramoto; L E Gibson; W M O'Fallon; S E Gabriel
Journal:  J Rheumatol       Date:  2000-05       Impact factor: 4.666

9.  Comparison of clinical and immunogenetic features in familial versus sporadic psoriatic arthritis.

Authors:  P Rahman; C T Schentag; M Beaton; D D Gladman
Journal:  Clin Exp Rheumatol       Date:  2000 Jan-Feb       Impact factor: 4.473

10.  TNF regulates thymocyte production by apoptosis and proliferation of the triple negative (CD3-CD4-CD8-) subset.

Authors:  J G Baseta; O Stutman
Journal:  J Immunol       Date:  2000-11-15       Impact factor: 5.422
View more
  25 in total

1.  Metabolic syndrome and its relationship with the achievement of minimal disease activity state in psoriatic arthritis patients: an observational study.

Authors:  Luisa Costa; Francesco Caso; Roberta Ramonda; Antonio Del Puente; Luca Cantarini; Md Abud Darda; Paolo Caso; Mariagrazia Lorenzin; Ugo Fiocco; Leonardo Punzi; Raffaele Scarpa
Journal:  Immunol Res       Date:  2015-02       Impact factor: 2.829

2.  Pattern VEP alterations in psoriatic patients may indicate a sub clinic optic neuritis.

Authors:  M Perossini; E Turio; T Perossini; M Romagnoli; S Benedetti; G Cei; P Barachini; M Nardi
Journal:  Doc Ophthalmol       Date:  2005 Mar-May       Impact factor: 2.379

Review 3.  Safety of etanercept in psoriasis: a critical review.

Authors:  Jose L Sánchez Carazo; Laura Mahiques Santos; Vicente Oliver Martinez
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

4.  Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial.

Authors:  D D Gladman; P J Mease; M A Cifaldi; R J Perdok; E Sasso; J Medich
Journal:  Ann Rheum Dis       Date:  2006-10-17       Impact factor: 19.103

5.  Impact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patients.

Authors:  Luisa Costa; Francesco Caso; Mariangela Atteno; Antonio Del Puente; Md Abud Darda; Paolo Caso; Augusta Ortolan; Ugo Fiocco; Roberta Ramonda; Leonardo Punzi; Raffaele Scarpa
Journal:  Clin Rheumatol       Date:  2014-06       Impact factor: 2.980

Review 6.  Heterogeneity of autoimmune diseases: pathophysiologic insights from genetics and implications for new therapies.

Authors:  Judy H Cho; Marc Feldman
Journal:  Nat Med       Date:  2015-06-29       Impact factor: 53.440

Review 7.  Outcome measures in psoriatic arthritis.

Authors:  Arthur Kavanaugh; Sarah Cassell
Journal:  Curr Rheumatol Rep       Date:  2005-06       Impact factor: 4.592

8.  TNF overproduction impairs epithelial staphylococcal response in hyper IgE syndrome.

Authors:  Ian A Myles; Erik D Anderson; Noah J Earland; Kol A Zarember; Inka Sastalla; Kelli W Williams; Portia Gough; Ian N Moore; Sundar Ganesan; Cedar J Fowler; Arian Laurence; Mary Garofalo; Douglas B Kuhns; Mark D Kieh; Arhum Saleem; Pamela A Welch; Dirk A Darnell; John I Gallin; Alexandra F Freeman; Steven M Holland; Sandip K Datta
Journal:  J Clin Invest       Date:  2018-07-23       Impact factor: 14.808

9.  RANKL cytokine enhances TNF-induced osteoclastogenesis independently of TNF receptor associated factor (TRAF) 6 by degrading TRAF3 in osteoclast precursors.

Authors:  Zhenqiang Yao; Wei Lei; Rong Duan; Yanyun Li; Lu Luo; Brendan F Boyce
Journal:  J Biol Chem       Date:  2017-04-24       Impact factor: 5.157

Review 10.  Altered bone remodeling in psoriatic arthritis.

Authors:  Kofi A Mensah; Edward M Schwarz; Christopher T Ritchlin
Journal:  Curr Rheumatol Rep       Date:  2008-08       Impact factor: 4.592
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.